Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Melanoma
Phase I UD expanded NK vs TGF-β–imprinted NK (intratumoral) in cSCC/BCC
Ohio State University Comprehensive Cancer Center compares standard UD expanded NK cells with TGF-β–imprinted NK cells in cutaneous SCC/BCC using diagnostic biopsy → intratumoral injection → surgical excision. Most…
NCT07144384 Exploratory - New trial Spotlight
Multiple solid tumors
Phase 1a/1b DB-1317 (ADAM9-directed Topo-I ADC) in advanced solid tumors (GI-leaning)
DualityBio’s first-in-human DB-1317 is Q3W, with accelerated titration/BOIN escalation then expansion in GI-heavy tumors (gastric, CRC, PDAC). GI cancers still depend on chemo with few durable targets; ADAM9…
NCT07141706 First-in-human - New trial Spotlight
Multiple solid tumors
Phase I BL-M05D1 CLDN18.2-directed Topo-I ADC (PDAC, biliary, G/GEJ & others)
SystImmune’s first-in-human study assesses safety/PK/efficacy of BL-M05D1 (IV Q3W) in CLDN18.2-expressing tumors, including PDAC, biliary tract cancer, and gastric/GEJ adenocarcinoma. Builds on CLDN18.2 momentum with…
NCT07021066 First-in-human - New trial
Multiple solid tumors
Phase II eVOLVE-02: volrustomig (MEDI5752; PD-1/CTLA-4 bispecific) ± combinations in advanced tumors (incl. HNSCC, cervical)
Academic sites with AstraZeneca are testing volrustomig (MEDI5752) as monotherapy and in volrustomig-based combinations (e.g., carboplatin/paclitaxel, cisplatin/5-FU) across tumor-specific sub-studies. CTLA-4/PD-1…
NCT06535607 Exploratory - New trial
Multiple solid tumors
Phase I SC-CAR.GPC3xIL15.21 pediatric/AYA CAR-T for GPC3+ non-CNS solid tumors (incl. HCC)
Seattle Children’s runs a first-in-human, single-infusion CAR-T armed with IL-15/21 plus an inducible safety switch for GPC3-positive tumors. Pediatric/AYA liver and other GPC3+ cancers (neuroblastoma) have sparse…
NCT07148050 First-in-human - New trial
Multiple solid tumors
Phase Ib IMA203 PRAME TCR-T + mRNA-4203 PRAME vaccine in melanoma/sarcoma
Immatics trials a first-in-human combo to amplify PRAME-specific T cells by pairing TCR-T with a PRAME mRNA vaccine. Post-IO melanoma needs deeper durability beyond ipi/nivo/TIL; synchronized vaccination may sustain…
NCT06946225 First-in-human - Trial result
Cervical and other gynecologic cancers
HPV16 L2/E7/E6 Vaccine (TA-CIN): Thigh Injection Yields Stronger Immunity Post-Treatment
TA-CIN is a recombinant HPV16 L2/E7/E6 fusion-protein therapeutic vaccine; in a randomized pilot (NCT02405221), 15 HPV16+ cervical cancer patients with no evidence of disease after primary therapy (stage IB1–IVA)…
NCT02405221 - Trial result
Brain and CNS tumors
Abemaciclib (CDK4/6) Hits 68% PFS6 in Recurrent Grade 2/3 Meningioma
Abemaciclib is an oral CDK4/6 inhibitor; in a multicenter basket trial (NCT03220646), an expanded cohort of recurrent meningioma (mostly grade 2–3; n=22) received 200 mg twice daily on 28-day cycles. The meningioma…
NCT03220646 - Trial result
Melanoma
Encorafenib+Binimetinib (BRAF/MEK) Produces Rapid LMD Response and ~14-mo Survival (Case)
Encorafenib (BRAF inhibitor) plus binimetinib (MEK inhibitor) were re-introduced at reduced doses in a 69-year-old man with BRAF V600K metastatic melanoma who developed leptomeningeal disease (LMD) and had declined…
NCT05026983 - Trial result
Ovarian cancer
SBRT (ablative radiotherapy) yields 95% 1-yr local control in oligorecurrent ovarian cancer
Stereotactic body radiation therapy (SBRT)—a high-dose, image-guided ablative radiotherapy—was tested in a Phase I 3+3 dose-escalation study (NCT03325634) for ovarian/fallopian tube/primary peritoneal cancers with ≤3…
NCT03325634 - Trial result Spotlight
Lymphoma
Haihe’s HH2853 (EZH1/2 dual) achieves 31% ORR, 16-mo mPFS in epithelioid sarcoma
HH2853 is an oral dual EZH1/2 histone-methyltransferase (PRC2) inhibitor; in an open-label, global Phase I dose-escalation/expansion (NCT04390737) across refractory solid tumors and NHL (n=61; 57 evaluable), seven…
NCT04390737 - New trial Spotlight
Colorectal cancer
Phase 2 Fruquintinib (VEGFR inhibitor) and Tislelizumab (PD-1 mAb) in MRD-Positive Colorectal Cancer
This Phase 2 trial, sponsored by M.D. Anderson, investigates whether fruquintinib—a VEGFR inhibitor small molecule—and tislelizumab, a PD-1–targeting monoclonal antibody, can reduce recurrence in stage II–IV…
NCT07136077 Exploratory - New trial
Colorectal cancer
Phase Ib/II Regorafenib (multikinase inhibitor) plus Lorigerlimab (PD-1/CTLA-4 bispecific) Neoadjuvant Trial for lung-limited mCRC
This Phase Ib/II study from MD Anderson Cancer Center is evaluating neoadjuvant treatment in patients with resectable, lung-limited metastatic colorectal cancer harboring pMMR/MSS tumors. Patients receive oral…
NCT07137390 Exploratory - New trial
Colorectal cancer
Phase 1b Botensilimab (CTLA-4 mAb) & Balstilimab (PD-1 inhibitor) + SBRT in CRC
This pilot feasibility study by Massachusetts General Hospital evaluates a single‐arm combination treatment in chemorefractory, MSS (non-MSI-H/proficient mismatch repair) colorectal cancer with liver metastasis.…
NCT07128355 Exploratory - New trial Spotlight
Lymphoma
Phase II Odronextamab bispecific CD20/CD3 antibody for follicular lymphoma
This Phase II study evaluates odronextamab, a CD20/CD3 bispecific monoclonal antibody, as monotherapy for treatment-naïve follicular lymphoma patients. It uses a multi-cycle dosing design with imaging, ECG, and…
NCT07128641 Exploratory - New trial
Lymphoma
Phase II Study: iC9/CD5CAR/IL-15 NK Cells CD5-targeted immunotherapy
This Phase II trial by MD Anderson explores the safety and efficacy of consolidation therapy using iC9/CD5CAR/IL-15 natural killer cells—engineered to target CD5 on aggressive T-cell lymphomas—in patients in first…
NCT07137481 Exploratory - New trial Spotlight
Acute myeloid leukemia and MDS
Phase I Trial of Lintuzumab-Ac-225, a CD33-targeted alpha emitter in AML
This Phase I study assesses the safety, tolerability, and optimal dosing of combination treatment with lintuzumab-Ac-225 (a CD33-targeted alpha emitter), venetoclax (a BCL-2 inhibitor), and ASTX-727 (a pairing of…
NCT06802523 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase 2 Olutasidenib IDH1 inhibitor AML maintenance trial
The study aims to assess whether the single-agent investigational olutasidenib, an IDH1 inhibitor, can safely maintain remission in adult patients with IDH1-mutant AML following intensive induction and consolidation…
NCT07130695 Exploratory - New trial
Non-small cell lung cancer
Phase 2 SAR445877 PD-1/IL-15 fusion protein immunotherapy for NSCLC
This Phase 2 biomarker study at MD Anderson Cancer Center evaluates SAR445877, an investigational immunotherapy from Sanofi (acquired with Kadmon in 2021) that combines a PD-1 antibody fused with a safer version of…
NCT07133425 Exploratory - New trial
Breast cancer
Phase I Trial of Avasopasem, a Superoxide Dismutase Mimetic, in Metastatic HR+ Breast Cancer
This trial evaluates the safety of adding Avasopasem—a superoxide dismutase mimetic—to CDK4/6 and hormonal (aromatase inhibitor) therapy in women with metastatic HR+ HER2– breast cancer that has progressed on…
NCT07137871 Exploratory - New trial
Prostate cancer
Phase 1 study of KTX2001 NSD2 inhibitor with darolutamide androgen receptor inhibitor
Study K36-MCRPC-001 is a first-in-human Phase 1 dose escalation trial by K36 Therapeutics, Inc., evaluating KTX2001—an NSD2 histone methyltransferase inhibitor—alone and with darolutamide, an androgen receptor…
NCT07103018 First-in-human - New trial Spotlight
Multiple myeloma
Phase Ib Talquetamab bispecific targeting GPRC5D/CD3 and Cilta-cel CAR-T (BCMA) in RRMM
This single-arm Phase 1b trial by the Medical College of Wisconsin evaluates the safety and feasibility of using talquetamab—a bispecific antibody targeting GPRC5D and CD3—as bridging therapy during CAR T-cell…
NCT07093554 Exploratory - New trial
Lung cancer
Phase 2 HEARTS trial: MRgART, MRI-guided adaptive radiotherapy targeting cardiac sparing in thoracic cancers.
This study compares an investigational MRgART that uses real-time imaging adjustments to spare the heart with standard LINAC radiation therapy employing stereotactic external beam delivery. Eligible patients include…
NCT07132918 Exploratory - New trial Spotlight
Brain and CNS tumors
Phase II Trial of LINAC Stereotactic Radiation, Delivering Precise DNA-Damaging Therapy for Brain Metastases
This study evaluates same-day adaptive LINAC-based stereotactic radiation comparing a 0mm versus a 1mm margin in patients with brain metastases from solid tumors. The design randomizes participants to receive…
NCT07132190 Exploratory - New trial
Liver and bile duct cancer
Phase 1 TheraBionic P1 device: Electromagnetic modulation therapy for advanced HCC
This trial assesses the safety and impact on overall survival of the investigational TheraBionic P1 device, which delivers self-administered amplitude-modulated electromagnetic fields, compared to a secondary…
NCT07118202 Exploratory - New trial Spotlight
Sarcoma and GIST
Phase II nab-Sirolimus trial: nanoparticle albumin-bound mTOR inhibitor for epithelioid hemangioendothelioma.
Investigating nab-Sirolimus in a non-randomized, open-label, single-arm Phase II trial, Sarcoma Alliance for Research through Collaboration assesses the objective response rate by RECIST v1.1 in patients with…
NCT07104331 Exploratory - New trial
Neuroendocrine and adrenal tumors
Phase I trial of [68Ga]Ga-FAPI-04, a fibroblast activation protein inhibitor for imaging.
This early phase I trial at University of Michigan Rogel Cancer Center evaluates the biodistribution and uptake of [68Ga]Ga-FAPI-04—a tracer that binds fibroblast activation protein—in patients with high-grade…
NCT07132645 Exploratory - New trial
Acute lymphoblastic leukemia
Phase 1/1b trial: Venetoclax BCL-2 inhibitor in relapsed B-cell ALL
This study evaluates the safety and effectiveness of combining asparaginase Erwinia chrysanthemi (protein synthesis inhibitor), venetoclax (BCL-2 inhibitor), and blinatumomab (bispecific T-cell engager) in adults…
NCT07133997 Exploratory - New trial
Sarcoma and GIST
Phase I trial: bland particles embolization with arterial occlusion for pediatric sarcomas
This phase I single-center, single-arm trial is evaluating the safety and feasibility of transarterial embolization using bland particles to occlude feeding vessels in hypervascular pediatric soft tissue sarcomas,…
NCT07136571 Exploratory - New trial Spotlight
Multiple solid tumors
Phase I study of AUBE00, an oral KRAS-targeting agent in solid tumors
This first-in-human Phase I study evaluates safety, pharmacokinetics, pharmacodynamics, immunogenicity, and anti-tumor activity of AUBE00 in patients with locally advanced or metastatic solid tumors harboring KRAS…
NCT07030959 First-in-human
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.